TY - JOUR T1 - Risk-based guidelines: Redefining management of abnormal cervical cancer screening results JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 556 LP - 560 DO - 10.3949/ccjm.88a.20193 VL - 88 IS - 10 AU - Amy Wiser AU - Jeffrey D. Quinlan AU - Pelin Batur Y1 - 2021/10/01 UR - http://www.ccjm.org/content/88/10/556.abstract N2 - In making the 2019 guidelines for risk-based management of patients with abnormal cervical cancer screening tests and cancer precursors, the guidelines committee shifted from results-based to risk-based management recommendations, based on the patient’s immediate and 5-year risks of grade 3 or higher cervical intraepithelial neoplasia (CIN 3+). The risk is determined by current and prior screening results (human papillomavirus infection, cytology testing) and the clinical history including age. An immediate 4% or higher risk of CIN 3+ was established as the dividing line between higher and lower risks, and the corresponding management recommendations. This article reviews the changes and their evidence base and discusses clinical implications of the revised guidelines. ER -